Why ProQR Therapeutics N.V.’s (PRQR) Stock Is Down 5.90%
As of Monday, August 31, ProQR Therapeutics N.V.’s PRQR share price has dipped by 5.90%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Commentary & Analysis
Why ProQR Therapeutics N.V.’s (PRQR) Stock Is Down 6.17%
As of Tuesday, August 25, ProQR Therapeutics N.V.’s PRQR share price has dipped by 6.17%, which has investors questioning if this is right time to buy.Jenna Brashear
Why ProQR Therapeutics N.V.’s (PRQR) Stock Is Up 5.19%
As of Wednesday, August 05, ProQR Therapeutics N.V.’s PRQR share price has surged by 5.19%, which has investors questioning if this is right time to sell.Jenna Brashear
Why ProQR Therapeutics N.V.’s (PRQR) Stock Is Up 9.09%
As of Tuesday, July 21, ProQR Therapeutics N.V.’s PRQR share price has surged by 9.09%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why ProQR Therapeutics N.V.’s (PRQR) Stock Is Up 5.39%
As of Friday, July 17, ProQR Therapeutics N.V.’s PRQR share price has surged by 5.39%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | PRQR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $292.1 | $282.4 | 31% |
|
| Shares Out (Mil) | 121.5 | 54.0 | 66% |
|
| Institutional Ownership | 94.7% | 93.1% | 65% |
|
| Float (Mil) | 91.4 | 42.2 | 59% |
|
| Beta | 0.03 | 0.94 | 7% |
|
| Avg Daily Volume (000s) | 866 | 482 | 70% |
|
| Price Change (52-week) |
(13.4%) | 59.9% | 35% |
|
| Growth | PRQR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 71.3% | 14.1% | 98% |
|
| Net Income (5yr) | 2.8% | (10.1%) | 44% |
|
| EPS (5yr) | 16.2% | 15.9% | 60 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 5.6% | (15.6%) | 67% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.108) | ($0.462) | ($0.473) | |
| Month Ago EPS | ($0.137) | ($0.605) | ($0.679) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.139) | ($0.616) | ($0.679) | |
| Year/Year Chg | (28.0%) | (1.7%) | 18.3% | |
| Financials | PRQR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $16 | $37 | 11% |
|
| Net Income (TTM) (Mil) | ($52) | ($43) | 16% |
|
| EPS (TTM) | ($0.498) | ($1.500) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($56) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($60) | $2 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $11 | $4 | 28% |
|
| Enterprise Value (Q1) (Mil) | $95 | $190 | 21% |
|
| Valuation | PRQR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.05 | 2.84 | 78% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | PRQR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.9% | 96% |
|
| Net Margin | (228.2%) | (74.2%) | 4% |
|
| ROA | (37.7%) | (47.7%) | 14% |
|
| ROE | (81.5%) | (55.0%) | 11% |
|
| Liabilities to Assets | 62.0% | 29.8% | 56% |
|
| F-Score | 2 | 3 | 7% |
|
ProQR Therapeutics N.V. did not pass any screens on 9/4/2026.
